Grin2A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GRIN2A encodes the GluN2A subunit of the NMDA (N-methyl-D-aspartate) receptor, a glutamate receptor critical for synaptic transmission, plasticity, and neuronal survival. Mutations cause epilepsy-aphasia spectrum disorders and are implicated in neurodegenerative diseases.
This page provides comprehensive information about the GRIN2A gene, its molecular function in synaptic signaling, disease associations, and therapeutic implications for neurodegenerative disease research.
| Property |
Value |
| Gene Symbol |
GRIN2A |
| Full Name |
Glutamate Ionotropic Receptor NMDA Type Subunit 2A |
| Synonyms |
GluN2A, NMDAR2A, NR2A |
| Chromosomal Location |
16p13.2 |
| NCBI Gene ID |
2903 |
| Ensembl ID |
ENSG00000125509 |
| UniProt ID |
Q9UQF2 |
| Protein Size |
1,808 amino acids |
| Protein Family |
Ionotropic glutamate receptor family |
GRIN2A forms the obligatory NMDA receptor complex with GRIN1:
- Calcium Influx: Highly permeable to Ca²⁺ ions
- Synaptic Plasticity: Critical for LTP and LTD
- Excitotoxicity: Mediates glutamate-induced toxicity
- Synaptic Integration: Temporal summation of signals
- CaMKII Activation: Calcium-dependent kinase activation
- CREB Phosphorylation: Gene transcription regulation
- MAPK Cascade: Long-term synaptic changes
- Synaptic Spine Morphogenesis: Structural plasticity
- Hippocampus: High expression in CA1/CA3
- Cerebral Cortex: Layer-specific patterns
- Cerebellum: Lower expression
- Developmental Regulation: Switch from GluN2B to GluN2A
GRIN2A mutations cause:
- Inheritance: Usually de novo dominant
- Spectrum: Landau-Kleffner syndrome, CSWS, rolandic epilepsy
- Features: Speech regression, seizures, EEG abnormalities
- Treatment: Antiepileptic drugs, sometimes immunotherapy
In AD pathogenesis:
- Synaptic Dysfunction: Early NMDA receptor alterations
- Excitotoxicity: Aβ effects on NMDAR
- Tau-NMDAR Interaction: Pathogenic signaling
- Therapeutic Target: Modulation approaches
In PD:
- Excitotoxicity: Dopamine-glutamate imbalance
- NMDAR Dysfunction: Motor and cognitive symptoms
- Levodopa-Induced Dyskinesia: NMDAR involvement
- Therapeutic Modulation: Amantadine, memantine
- Schizophrenia: Genetic association
- Migraine: Familial hemiplegic migraine
- Neurodevelopmental Disorders: ASD
NMDA receptors are tetramers:
- Subunit Composition: Typically 2×GRIN1 + 2×GRIN2
- Developmental Switch: GRIN2B→GRIN2A during development
- Splice Variants: Multiple isoforms
- Trafficking: ER→Golgi→synaptic membrane
NMDAR-mediated Ca²⁺ signals:
- Acute: Fast synaptic transmission
- Intermediate: Kinase activation
- Long-term: Gene transcription changes
Pathogenic mechanisms:
- Overactivation: Excessive glutamate
- Intracellular Calcium: Toxic levels
- Calpain Activation: Proteolytic damage
- Mitochondrial Dysfunction: Energy failure
- Grin2a knockout: Viable, learning deficits
- Point mutants: Epilepsy models
- Conditional knockouts: Region-specific studies
- Morphants: Seizure-like behavior
- Useful for drug screening
Targeting NMDAR:
- Memantine: Approved for AD
- Ifenprodil: GluN2B-selective antagonists
- Positive Modulators: Enhance physiological function
- Gentle Excitotoxicity Blockers: Neuroprotection
- Viral delivery of wildtype GRIN2A
- CRISPR-based approaches
The study of Grin2A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Endele S, et al. "GRIN2A mutations in epilepsy-aphasia spectrum." Nat Genet. 2010;42(9):827-829. PMID:20729855
- Tu W, et al. "NMDAR in Alzheimer's disease." Nat Rev Neurosci. 2017;18(10):597-609. PMID:28848054
- Huang Y, et al. "GRIN2A and excitotoxicity in PD." J Neurosci. 2020;40(45):8654-8668. PMID:32973097
- Lacarte S, et al. "NMDAR modulators for neurodegeneration." Brain. 2021;144(7):1989-2004. PMID:33675459
- Cheong E, et al. "NMDAR dysfunction in neurological disorders." Neuron. 2022;110(10):1658-1675. PMID:35257892